Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies

The phase 3 POLLUX and CASTOR studies demonstrated superior benefit of daratumumab plus lenalidomide/dexamethasone or bortezomib/dexamethasone in relapsed/refractory multiple myeloma. Efficacy and safety of daratumumab was analyzed according to age groups of 65 to 74 years and ≥75 years. Patients re...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Haematologica
Autores principales: Mateos, Maria-Victoria, Spencer, Andrew, Nooka, Ajay K., Pour, Ludek, Weisel, Katja, Cavo, Michele, Laubach, Jacob P., Cook, Gordon, Iida, Shinsuke, Benboubker, Lotfi, Usmani, Saad Z., Yoon, Sung-Soo, Bahlis, Nizar J., Chiu, Christopher, Ukropec, Jon, Schecter, Jordan M., Qin, Xiang, O’Rourke, Lisa, Dimopoulos, Meletios A.
Formato: Artigo
Lenguaje:Inglês
Publicado: Ferrata Storti Foundation 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7012498/
https://ncbi.nlm.nih.gov/pubmed/31221782
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.217448
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares